Clostridial spores for cancer therapy: targeting solid tumour microenvironment

Area of Science:

• Oncology
• Microbiology
• Biotechnology

Background:

• Solid tumors constitute 90% of all cancers, with current treatments like surgery, chemotherapy, and radiotherapy having significant limitations.
• Traditional cancer research focused on targeting tumor cells directly, but recent advances emphasize exploiting the tumor microenvironment (TME).
• The TME presents unique characteristics, such as hypoxia and necrosis, which can be leveraged for targeted cancer therapies.

Purpose of the Study:

• To review the characteristics of the tumor microenvironment.
• To summarize the progress and current status of Clostridium spore-based cancer therapies.
• To highlight the potential of anaerobic bacteria for selective tumor targeting and destruction.

Main Methods:

• Review of existing literature on tumor microenvironment and anaerobic bacterial therapies.
• Focus on the selective colonization and therapeutic potential of anaerobic bacteria, specifically Clostridium species.
• Analysis of Clostridium's ability to penetrate and colonize hypoxic and necrotic tumor regions.

Main Results:

• Anaerobic bacteria, including Clostridium, demonstrate selective colonization of solid tumors.
• Clostridium species effectively penetrate and colonize hypoxic and necrotic areas within the tumor microenvironment.
• This colonization leads to significant oncolysis (tumor cell destruction) and facilitates in situ delivery of therapeutics.

Conclusions:

• Exploiting the tumor microenvironment, particularly hypoxic and necrotic regions, using anaerobic bacteria is a promising cancer treatment strategy.
• Clostridium spores show significant potential for selective tumor targeting, destruction, and localized drug delivery.
• Clostridial spore-based therapies represent a novel and emerging area in cancer treatment research.